Back

Potential Implications of Expanded FDA Labeling for Sacubitril/Valsartan in the United States

29 June 2021 (08:00 - 08:00)
Organised by:
Congress Presentation Part of: Registry Updates Pharmacotherapy HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Muthiah Vaduganathan

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

10 More presentations in this session

Presentation thumbnail
SCD and ventricular event rates in a Japanese population: Primary results from the Heart Failure Indication and Sudden Cardiac Death Prevention Trial
Doctor K. Aonuma (Tsukuba, JP)
Slides Video
Presentation thumbnail
Clinical course and related costs of patients with type 2 diabetes and heart failure and/or chronic kidney disease, drawn from a sample of more than 7 million people
Doctor A. Maggioni (Florence, IT)
Slides Video
Presentation thumbnail
Prescription Fill Patterns of Guideline-Directed Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
Higher Alkaline Phosphatase Mean and Variability Predict Heart Failure and All-cause Mortality
Ms S. Lee (Hong Kong, CN)
Slides Video
Presentation thumbnail
Heart Failure Drug Titration, Discontinuation and Mortality and HF Hospitalization Risk: A Multinational Observational Study (US, UK and Sweden)
Professor G. Savarese (Stockholm, SE)
Slides Video

Access the full session

Session thumbnail
Registry Updates

The Event

Event poster

Heart Failure 2021

29 June 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Sacubitril/Valsartan efficacy on functional, laboratory, echocardiographic parameters: a real-world study
29 June 2021
thumbnail
Webinar
MRAs in heart failure: what's old is new again
10 July 2023
thumbnail
Congress Session
Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?
30 August 2025
thumbnail
ESC Journals
66 Relative efficacy of sacubitril/valsartan, dapagliflozin and vericiguat: a systematic review and network meta-analysis
17 December 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources